Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.61 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | FUT8 | Q9BYC5 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.47 |
| ▸ | MPL | P40238 | 3/20 | 0.46 |
| ▸ | CTRC | Q99895 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472408 | 1.00 | CYP1A2 (0.62) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL29050868 | 0.99 | CYP1A2 (0.61) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL4939211 | 0.99 | CYP1A2 (0.65) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL29050875 | 0.91 | CYP1A2 (0.54) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL6229887 | 0.86 | CYP1A2 (0.74) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL13763680 | 0.86 | CYP1A2 (0.64) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL8453667 | 0.86 | CYP1A2 (0.74) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL7586572 | 0.86 | CYP1A2 (0.64) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL7586578 | 0.86 | CYP1A2 (0.64) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 | |
| SCHEMBL8771585 | 0.84 | ENPP2 (0.57) | CYP1A2MAPK1CYP2C9DNASE1L3PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8294282-B2 | Semiconductor device and adhesive sheet | KABUSHIKI KAISHA TOSHIBA (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110068480-A1 | SEMICONDUCTOR DEVICE AND ADHESIVE SHEET | TOSHIBA MEMORY CORPORATION (JP) | 2011-03-24 | — | — | US | disclosed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | AMBION, INC (US) | 2007-02-08 | — | — | US | disclosed |
| US-6498132-B2 | SURFACE TREATMENT COMPOSITION COMPRISES A COMPLEXING AGENT AS A METAL DEPOSITION PREVENTIVE COMPRISING ATLEAST ONE AROMATIC HYDROCARBON RING CONTAINING HYDROXY OR O-GROUP DIRECTLY ATTACHED WITH RING CARBON AND A SECOND COMPLEXING AGENT | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-12-24 | — | — | US | disclosed |
| US-20020045556-A1 | Method for treating surface of substrate and surface treatment composition used for the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-04-18 | — | — | US | disclosed |
| US-5885362-A | APPLYING TO SURFACE A COMPOSITION COMPRISING A LIQUID MEDIUM AND AT LEAST ONE COMPLEXING AGENT, FOR EXAMPLE ETHYLENEDIAMINEDIORTHOHYDROXYPHENYLACETIC ACID | MITSUBISHI CHEMICAL CORPORATION (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5790627-A | Method and apparatus for observing a specimen using an X-ray microscope | RESEARCH DEVELOPMENT CORP. (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0789071-A1 | METHOD FOR TREATING SURFACE OF SUBSTRATE AND SURFACE TREATMENT COMPOSITION THEREFOR | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | RNASE1, RNASEH1, RNASEL | CYP1A2 4375/4885MAPK1 3346/4885CYP2C9 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.